nafamostat has been researched along with Stroke in 3 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors retrospectively identified the patients who received nafamostat mesilate and who suffered symptomatic ischemic stroke within 30 postoperative days." | 7.78 | Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass. ( Hiraiwa, T; Kikura, M; Tanaka, K, 2012) |
| "NM treatment attenuated the brain infarct volume and the loss of body weight and improved the recovery of sensorimotor and cognitive functions." | 5.46 | Nafamostat Mesilate Improves Neurological Outcome and Axonal Regeneration after Stroke in Rats. ( Fang, Y; Li, C; Liao, H; Liu, Y; Sun, H; Tao, X; Wang, J; Zhou, XF, 2017) |
| "The authors retrospectively identified the patients who received nafamostat mesilate and who suffered symptomatic ischemic stroke within 30 postoperative days." | 3.78 | Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass. ( Hiraiwa, T; Kikura, M; Tanaka, K, 2012) |
| "NM treatment attenuated the brain infarct volume and the loss of body weight and improved the recovery of sensorimotor and cognitive functions." | 1.46 | Nafamostat Mesilate Improves Neurological Outcome and Axonal Regeneration after Stroke in Rats. ( Fang, Y; Li, C; Liao, H; Liu, Y; Sun, H; Tao, X; Wang, J; Zhou, XF, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Li, C | 1 |
| Wang, J | 1 |
| Fang, Y | 1 |
| Sun, H | 1 |
| Tao, X | 1 |
| Zhou, XF | 1 |
| Liao, H | 1 |
| Kikura, M | 1 |
| Tanaka, K | 2 |
| Hiraiwa, T | 1 |
| Morimoto, N | 1 |
| Henmi, S | 1 |
| Yoshida, M | 1 |
| Mukohara, N | 1 |
3 other studies available for nafamostat and Stroke
| Article | Year |
|---|---|
Nafamostat Mesilate Improves Neurological Outcome and Axonal Regeneration after Stroke in Rats.
Topics: Animals; Axons; Benzamidines; Body Weight; Brain Infarction; Cognition; Cyclic AMP Response Element- | 2017 |
Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.
Topics: Aged; Benzamidines; Brain Ischemia; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cohort Stud | 2012 |
Cardiopulmonary bypass strategy with low-dose heparin and nafamostat mesilate in cardiac surgery: a safe option for patients with acute stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzamidines; Cardiac Surgical Procedures; Cardiopulmonary | 2012 |